Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
3
×
life sciences
national blog main
new york blog main
boston
boston top stories
clinical trials
new york top stories
alirocumab
alnylam pharmaceuticals
amgen
azacitidine
beta-thalassemia
cancer
codiak biosciences
cutaneous t-cell lymphoma
dacogen
deals
decitabine
dna
drugs
epigenetics
epizyme
evercore isi
evolocumab
exosome
farydak
flagship pioneering
fulcrum therapeutics
heart attack
inclisiran
insulated genomic domains
jazz pharmaceuticals
joseph swartz
kaleido biosciences
mahesh karande
medicines co.
national top stories
new york
What
based
3
×
medicines
new
3
×
aims
alnylam
approach
begin
biosciences
biotech
bio’s
brings
bubbles
called
cells
cholesterol
class
clinical
codiak
data
debuts
developing
drug
drugs
epigenetic
epigenetics
evidence
exosome
exosomes
field
flagship’s
formed
fund
heart
ipo
lasting
long
looms
lowering
medco
million
Language
unset
Current search:
xconomy.com
×
based
×
new
×
" boston blog main "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms